Literature DB >> 17301813

Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome.

P K Epling-Burnette1, J S Painter, D E Rollison, E Ku, D Vendron, R Widen, D Boulware, J X Zou, F Bai, A F List.   

Abstract

Selected patients with Myelodysplastic Syndromes (MDS) are responsive to immunosuppressive therapy, suggesting that hematopoietic suppressive T cells have a pathogenic role in ineffective hematopoiesis. We assessed T-cell receptor (TCR) clonality through combined flow cytometry and molecular analysis of the complementarity determining region (CDR)-3 of the T-cell receptor-Vbeta gene. We identified clonal T cells in 50% of MDS patients (n=52) compared to 5% of age-matched normal controls (n=20). The presence of T-cell clones was not associated with features linked previously to immunosuppression response, including WHO diagnostic category, karyotype, marrow cellularity, IPSS category, sex or age <or=60. Using flow cytometry to identify expanded Vbeta-families, we found that T cells showed greater expansion in the bone marrow compared with peripheral blood, and were characterized as CD8(+)/CD57(+)/CD28(-) effector T cells. Expanded effector T cell were CD62L negative and expressed the natural killer C-lectin-family receptor NKG2D and CD244 (2B4). We conclude that clonal T-cell expansion is common among all MDS prognostic subgroups.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301813     DOI: 10.1038/sj.leu.2404590

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  34 in total

1.  A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.

Authors:  John J Powers; Jason A Dubovsky; P K Epling-Burnette; Lynn Moscinski; Ling Zhang; Satu Mustjoki; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Lymphoma       Date:  2011-01-27

Review 2.  Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.

Authors:  Tapan M Kadia; Elias Jabbour; Hagop Kantarjian
Journal:  Semin Oncol       Date:  2011-10       Impact factor: 4.929

Review 3.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 4.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

5.  Unusual association of paroxysmal cold hemoglobinuria as the first sign of disease in myelodysplastic patient.

Authors:  Caterina Stefanizzi; Massimo Breccia; Michelina Santopietro; Serelina Coluzzi; Laura Cannella; Gabriella Girelli; Giuliana Alimena
Journal:  Int J Hematol       Date:  2009-05-26       Impact factor: 2.490

6.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.

Authors:  Martine E D Chamuleau; Theresia M Westers; Linda van Dreunen; Judith Groenland; Adri Zevenbergen; Corien M Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

7.  Fibrosis and subsequent cytopenias are associated with basic fibroblast growth factor-deficient pluripotent mesenchymal stromal cells in large granular lymphocyte leukemia.

Authors:  Adam W Mailloux; Ling Zhang; Lynn Moscinski; John M Bennett; Lili Yang; Sean J Yoder; Gregory Bloom; Cody Wei; Sheng Wei; Lubomir Sokol; Thomas P Loughran; Pearlie K Epling-Burnette
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

8.  Comparison of BIOMED-2 versus laboratory-developed polymerase chain reaction assays for detecting T-cell receptor-gamma gene rearrangements.

Authors:  Keyur P Patel; Qiulu Pan; Yanhua Wang; Robert W Maitta; Juan Du; Xiaonan Xue; Juan Lin; Howard Ratech
Journal:  J Mol Diagn       Date:  2010-03       Impact factor: 5.568

9.  Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Authors:  H Suen; R Brown; S Yang; C Weatherburn; P J Ho; N Woodland; N Nassif; P Barbaro; C Bryant; D Hart; J Gibson; D Joshua
Journal:  Leukemia       Date:  2016-04-22       Impact factor: 11.528

10.  High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease.

Authors:  Yoshimi Enose-Akahata; Eiji Matsuura; Unsong Oh; Steven Jacobson
Journal:  PLoS Pathog       Date:  2009-12-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.